{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T13:27:00Z","timestamp":1772112420633,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.brachy.2025.12.003","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T04:59:50Z","timestamp":1767761990000},"page":"313-324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective study on tumor control, survival, toxicity and quality of life after EBRT and an HDR-brachytherapy boost in intermediate to high-risk prostate cancer patients"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7981-5768","authenticated-orcid":false,"given":"Max","family":"Peters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1375-3920","authenticated-orcid":false,"given":"Tonnis T.","family":"Nuver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marnix J.A.","family":"Rasing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margo C.","family":"Noordhoek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie A.D.","family":"Haverkort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik C.","family":"Schimmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wout J.","family":"Schoevers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0901-3004","authenticated-orcid":false,"given":"Michal D.","family":"Czerwinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4243-8388","authenticated-orcid":false,"given":"Peter S.N.","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.J.","family":"Kattevilder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3585-2919","authenticated-orcid":false,"given":"Andr\u00e9 W.","family":"Minken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.brachy.2025.12.003_bib0001","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.brachy.2025.12.003_bib0002","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.brachy.2025.12.003_bib0003","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2022.11.005","article-title":"An updated analysis of the survival endpoints of ASCENDE-RT","volume":"115","author":"Oh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2025.12.003_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2022.109460","article-title":"Outcomes following brachytherapy boost for intermediate- and high-risk prostate cancer: a retrospective bicenter study by the SFRO brachytherapy group","volume":"180","author":"Ka","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2025.12.003_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109632","article-title":"Brachytherapy boost improves survival and decreases risk of developing distant metastases compared to external beam radiotherapy alone in intermediate and high risk group prostate cancer patients","volume":"183","author":"Miszczyk","year":"2023","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.brachy.2025.12.003_bib0006","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","article-title":"Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.brachy.2025.12.003_bib0007","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.semradonc.2019.08.003","article-title":"HDR prostate brachytherapy","volume":"30","author":"Crook","year":"2020","journal-title":"Semin Radiat Oncol"},{"issue":"9","key":"10.1016\/j.brachy.2025.12.003_bib0008","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/jama.2018.0587","article-title":"Radical prostatectomy, external beam radiotherapy, or external beam radiotherapy with brachytherapy boost and disease progression and mortality in patients with Gleason score 9\u201310 prostate cancer","volume":"319","author":"Kishan","year":"2018","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.brachy.2025.12.003_bib0009","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.6871","article-title":"Interplay between duration of androgen deprivation therapy and external beam radiotherapy with or without a brachytherapy boost for optimal treatment of high-risk prostate cancer: a patient-level data analysis of 3 cohorts","volume":"8","author":"Kishan","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.brachy.2025.12.003_bib0010","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ijrobp.2023.08.046","article-title":"Trimodality therapy with Iodine-125 brachytherapy, external beam radiation therapy, and short- or long-term androgen deprivation therapy for high-risk localized prostate cancer: results of a multicenter, randomized phase 3 trial (TRIP\/TRIGU0907)","volume":"118","author":"Yorozu","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.brachy.2025.12.003_bib0011","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.brachy.2013.08.001","article-title":"High-dose-rate prostate brachytherapy based on registered transrectal ultrasound and in-room cone-beam CT images","volume":"13","author":"Even","year":"2014","journal-title":"Brachytherapy"},{"issue":"446","key":"10.1016\/j.brachy.2025.12.003_bib0012","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.brachy.2025.12.003_bib0013","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.radonc.2020.09.047","article-title":"Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: mature 12-year results","volume":"154","author":"Hoskin","year":"2021","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.brachy.2025.12.003_bib0014","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.euo.2023.11.018","article-title":"A systematic review of the efficacy and toxicity of brachytherapy boost combined with external beam radiotherapy for nonmetastatic prostate cancer","volume":"7","author":"Slevin","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.brachy.2025.12.003_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.brachy.2025.12.003_bib0016","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00345-023-04745-w","article-title":"Focal radiotherapy boost to MR-visible tumor for prostate cancer: a systematic review","volume":"42","author":"Dornisch","year":"2024","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.brachy.2025.12.003_bib0017","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.euo.2022.10.001","article-title":"Magnetic Resonance Imaging\u2013guided focal boost to intraprostatic lesions using external beam radiotherapy for localized prostate cancer: a systematic review and meta-analysis","volume":"6","author":"Poon","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.brachy.2025.12.003_bib0018","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13014-017-0884-y","article-title":"Nadir PSA is a strong predictor of treatment outcome in intermediate and high risk localized prostate cancer patients treated by definitive external beam radiotherapy and androgen deprivation","volume":"12","author":"Geara","year":"2017","journal-title":"Radiat Oncol"},{"issue":"4","key":"10.1016\/j.brachy.2025.12.003_bib0019","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.ijrobp.2005.07.006","article-title":"PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis","volume":"64","author":"Ray","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.brachy.2025.12.003_bib0020","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.prro.2013.05.008","article-title":"Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy","volume":"4","author":"Jackson","year":"2014","journal-title":"Pract Radiat Oncol"},{"issue":"1","key":"10.1016\/j.brachy.2025.12.003_bib0021","first-page":"52","article-title":"PSA nadir predicts biochemical recurrence after external beam radiation therapy combined to high dose rate brachytherapy in the treatment of prostate cancer","volume":"10","author":"Coelho","year":"2022","journal-title":"Am J Clin Exp Urol"},{"issue":"2","key":"10.1016\/j.brachy.2025.12.003_bib0022","doi-asserted-by":"crossref","first-page":"95","DOI":"10.5114\/jcb.2016.59686","article-title":"Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer","volume":"8","author":"Tsumura","year":"2016","journal-title":"J Contemp Brachytherapy"},{"issue":"1","key":"10.1016\/j.brachy.2025.12.003_bib0023","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.brachy.2018.08.013","article-title":"Radical dose escalation by high-dose-rate brachytherapy for localized prostate cancer-significance of prostate-specific antigen nadir level within 18 months as correlation for long-term biochemical control","volume":"18","author":"Schroeder","year":"2019","journal-title":"Brachytherapy"},{"issue":"2","key":"10.1016\/j.brachy.2025.12.003_bib0024","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.radonc.2016.09.016","article-title":"A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients","volume":"121","author":"Joseph","year":"2016","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.brachy.2025.12.003_bib0025","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.radonc.2015.02.023","article-title":"High dose-rate brachytherapy boost for intermediate risk prostate cancer: long-term outcomes of two different treatment schedules and early biochemical predictors of success","volume":"115","author":"Helou","year":"2015","journal-title":"Radiother Oncol"},{"issue":"4","key":"10.1016\/j.brachy.2025.12.003_bib0026","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200195","article-title":"Meta-analysis of candidate surrogate end points in advanced prostate cancer","volume":"2","author":"Gharzai","year":"2023","journal-title":"NEJM Evid"},{"issue":"3","key":"10.1016\/j.brachy.2025.12.003_bib0027","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1470-2045(24)00016-0","article-title":"Surrogate endpoints in clinical trials of p16-positive squamous cell carcinoma of the oropharynx: an individual patient data meta-analysis","volume":"25","author":"Gharzai","year":"2024","journal-title":"Lancet Oncol"},{"issue":"32","key":"10.1016\/j.brachy.2025.12.003_bib0028","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.23.00617","article-title":"Biochemical recurrence surrogacy for clinical outcomes after radiotherapy for adenocarcinoma of the prostate","volume":"41","author":"Roy","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.brachy.2025.12.003_bib0029","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.brachy.2025.12.003_bib0030","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.brachy.2025.12.003_bib0031","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/j.ijrobp.2011.04.005","article-title":"Radiotherapy doses of 80 gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer","volume":"82","author":"Pahlajani","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.brachy.2025.12.003_bib0032","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijrobp.2024.02.064","article-title":"A randomized trial comparing quality of life after low-dose rate or high-dose rate prostate brachytherapy boost with pelvic external beam radiation therapy","volume":"120","author":"Crook","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.brachy.2025.12.003_bib0033","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ijrobp.2017.02.027","article-title":"ASCENDE-RT: an analysis of health-related quality of life for a randomized trial comparing low-dose-rate brachytherapy boost with dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.brachy.2025.12.003_bib0034","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.brachy.2025.12.003_bib0035","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.radonc.2017.06.012","article-title":"High-dose-rate brachytherapy boost for prostate cancer treatment: different combinations of hypofractionated regimens and clinical outcomes","volume":"124","author":"Vigneault","year":"2017","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.brachy.2025.12.003_bib0036","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.brachy.2020.10.002","article-title":"Risk factors for urethral stricture following external beam radiotherapy and HDR brachytherapy for prostate cancer","volume":"20","author":"Groom","year":"2021","journal-title":"Brachytherapy"},{"issue":"7","key":"10.1016\/j.brachy.2025.12.003_bib0037","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.clon.2017.01.042","article-title":"Long-term toxicity and health-related quality of life after single-fraction high dose rate brachytherapy boost and hypofractionated external beam radiotherapy for intermediate-risk prostate cancer","volume":"29","author":"Shahid","year":"2017","journal-title":"Clin Oncol (R Coll Radiol)."},{"issue":"10231","key":"10.1016\/j.brachy.2025.12.003_bib0038","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.brachy.2025.12.003_bib0039","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.eururo.2022.10.024","article-title":"Incorporating prostate-specific membrane antigen positron emission tomography in management decisions for men with newly diagnosed or biochemically recurrent prostate cancer","volume":"83","author":"Bukavina","year":"2023","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.brachy.2025.12.003_bib0040","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00259-020-04782-2","article-title":"(18)F-DCFPyL PET\/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy","volume":"48","author":"Wondergem","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.brachy.2025.12.003_bib0041","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2967\/jnumed.117.197160","article-title":"The impact of (68)Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study","volume":"59","author":"Roach","year":"2018","journal-title":"J Nucl Med"}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472125003691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472125003691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T12:41:51Z","timestamp":1772109711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472125003691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1538472125003691"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2025.12.003","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective study on tumor control, survival, toxicity and quality of life after EBRT and an HDR-brachytherapy boost in intermediate to high-risk prostate cancer patients","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2025.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Brachytherapy Society. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}